Oral Carbon Monoxide Therapeutic to Prevent Vaso-Occlusive Crises in Sickle Cell Disease

口服一氧化碳治疗可预防镰状细胞病的血管闭塞危机

基本信息

  • 批准号:
    9257461
  • 负责人:
  • 金额:
    $ 4.16万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2016
  • 资助国家:
    美国
  • 起止时间:
    2016-04-07 至 2017-12-31
  • 项目状态:
    已结题

项目摘要

 DESCRIPTION (provided by applicant): The overall objective of the proposed project is to investigate the potential of the gasotransmitter carbon monoxide (CO) as an anti-inflammatory agent in Sickle Cell Disease (SCD) using a novel oral formulation of CO (HBI-002). Numerous studies, both in vitro and in vivo, demonstrate that CO has cytoprotective properties through anti-oxidant, anti-inflammatory and anti-apoptotic processes. Researchers found in three studies using four different transgenic sickle cell mouse models that the heme oxygenase-1/CO pathway is key in SCD and demonstrated that very low doses of CO are a novel approach to limiting vascular stasis and down-regulating the inflammatory process. These studies provide compelling support for a potential beneficial role for CO in limiting the morbidity of SCD. Moreover, Phase 1 clinical studies of CO in both normal volunteers and SCD patients using a variety of CO delivery mechanisms have demonstrated the tolerability and safety of CO, suggesting that the very low targeted levels of COHb will not be associated with adverse outcomes. HBI-002, an oral liquid formulation, is being developed for the treatment of SCD. The oral administration of a defined dose of CO delivered by HBI-002 obviates the problems associated with previously studied inhaled or carrier-metal CO administration, enabling the potential for the necessary chronic, safe, non-toxic outpatient dosing of CO. HBI-002 comprises CO in a water-based solution of proprietary excipients to maximize CO content. Proof-of-concept manufacture of HBI-002 has been demonstrated. Pharmacokinetic and pharmacodynamic studies in rats and in two adult healthy volunteers have demonstrated proof-of-concept feasibility, tolerability, and bioavailability. The next step in development is to demonstrate that CO delivered from HBI-002 improves outcomes in an appropriate SCD animal model and to determine the minimum effective dose in SCD mice to inform dosing in planned clinical trials.
 描述(由申请人提供):拟议项目的总体目标是使用新型CO口服制剂(HBI-002)研究气体递质一氧化碳(CO)作为镰状细胞病(SCD)抗炎剂的潜力。大量的体外和体内研究表明,CO通过抗氧化、抗炎和抗凋亡过程具有细胞保护特性。研究人员在三项使用四种不同转基因镰状细胞小鼠模型的研究中发现,血红素加氧酶-1/CO途径是SCD的关键,并证明极低剂量的CO是限制血管淤滞和下调炎症过程的新方法。这些研究为CO在限制SCD发病率方面的潜在有益作用提供了令人信服的支持。此外,使用各种CO递送机制在正常志愿者和SCD患者中进行的CO的I期临床研究已经证明了CO的耐受性和安全性,表明非常低的COHb目标水平与不良结局无关。HBI-002是一种口服液体制剂,正在开发用于治疗SCD。通过HBI-002递送的限定剂量的CO的口服给药避免了与先前研究的吸入或载体金属CO给药相关的问题,使得能够进行必要的慢性、安全、无毒的门诊CO给药。HBI-002在专有赋形剂的水基溶液中包含CO以使CO含量最大化。HBI-002的概念验证生产已经得到证实。在大鼠和两名成年健康志愿者中进行的药代动力学和药效学研究证明了概念验证的可行性、耐受性和生物利用度。开发的下一步是证明从HBI-002递送的CO改善适当SCD动物模型中的结果,并确定SCD小鼠中的最小有效剂量,以告知计划的临床试验中的给药。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOHN D BELCHER其他文献

JOHN D BELCHER的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOHN D BELCHER', 18)}}的其他基金

Oral N2O Therapy in Treating Acute Vaso-Occlusive Pain in Sickle Cell Disease
口服 N2O 疗法治疗镰状细胞病急性血管闭塞性疼痛
  • 批准号:
    10507724
  • 财政年份:
    2022
  • 资助金额:
    $ 4.16万
  • 项目类别:
Circulating Endothelial Cells and Microvesicles as Biomarkers for Gene Therapy in Sickle Cell Disease
循环内皮细胞和微泡作为镰状细胞病基因治疗的生物标志物
  • 批准号:
    10012207
  • 财政年份:
    2019
  • 资助金额:
    $ 4.16万
  • 项目类别:
HBI-002 to Prevent Vaso-Occlusive Crises in Sickle Cell Disease
HBI-002 可预防镰状细胞病的血管闭塞危机
  • 批准号:
    9789371
  • 财政年份:
    2016
  • 资助金额:
    $ 4.16万
  • 项目类别:
BIOLOGICAL MARKERS OF ALCOHOL CONSUMPTION
饮酒的生物标志物
  • 批准号:
    3111772
  • 财政年份:
    1989
  • 资助金额:
    $ 4.16万
  • 项目类别:
BIOLOGICAL MARKERS OF ALCOHOL CONSUMPTION
饮酒的生物标志物
  • 批准号:
    2044165
  • 财政年份:
    1989
  • 资助金额:
    $ 4.16万
  • 项目类别:
BIOLOGICAL MARKERS OF ALCOHOL CONSUMPTION
饮酒的生物标志物
  • 批准号:
    3111775
  • 财政年份:
    1989
  • 资助金额:
    $ 4.16万
  • 项目类别:

相似海外基金

Investigating how TRAF1 Controls Inflammasome Activation in Animal Disease Models of Inflammatory Arthritis and Peritonitis
研究 TRAF1 如何控制炎症性关节炎和腹膜炎动物疾病模型中的炎症小体激活
  • 批准号:
    449429
  • 财政年份:
    2020
  • 资助金额:
    $ 4.16万
  • 项目类别:
    Studentship Programs
Establishment of animal disease models for intractable pediatric diseases due to defects of RNA metabolism and development of new therapeutics
RNA代谢缺陷引起的儿科疑难疾病动物模型的建立及新疗法的开发
  • 批准号:
    20H03644
  • 财政年份:
    2020
  • 资助金额:
    $ 4.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
Functional analysis of type 2 diabetes susceptibility genes using animal disease models
利用动物疾病模型对2型糖尿病易感基因进行功能分析
  • 批准号:
    18K08466
  • 财政年份:
    2018
  • 资助金额:
    $ 4.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Cell therapy of adipocytes derived from human iPS cells using cellcontainers and animal disease models
使用细胞容器和动物疾病模型对源自人类 iPS 细胞的脂肪细胞进行细胞治疗
  • 批准号:
    24659444
  • 财政年份:
    2012
  • 资助金额:
    $ 4.16万
  • 项目类别:
    Grant-in-Aid for Challenging Exploratory Research
Analysis of genes involved in the pathogenesis of the arthritis using animal disease models..
使用动物疾病模型分析涉及关节炎发病机制的基因。
  • 批准号:
    17500284
  • 财政年份:
    2005
  • 资助金额:
    $ 4.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
ESTABLISHMENT OF THE DEVELOPING AND SUPPLING SYSTEMS FOR NEW ANIMAL,DISEASE MODELS FROM SUBSPECIES OF THE MOUSE
小鼠亚种新动物、疾病模型的开发和供应体系的建立
  • 批准号:
    07556128
  • 财政年份:
    1995
  • 资助金额:
    $ 4.16万
  • 项目类别:
    Grant-in-Aid for Scientific Research (A)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了